Lumito publishes prospectus in connection with issue of warrants
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, BELARUS, RUSSIA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER […]
Lumito notifies changes to terms for the issue of free-of-charge warrants
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, BELARUS, RUSSIA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER […]
Lumito secures loan of SEK 20 million and carries out an issue of warrants free-of-charge to shareholders and the lender
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, BELARUS, RUSSIA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER […]
Lumito AB publishes Quarterly Report 3, 2023
Financial overview of the third quarterJuly 1 to September 30, 3023 Net sales amounted to TSEK 0 (0). Result after taxes amounted to TSEK -5 358 (-6 815). Earnings per share before and after dilution amounted to SEK -0,03 (-0,04). Cash flow from operating activities after changes in working capital amounted to TSEK -6 101 […]
Lumito signs an agreement with Uniogen Oy
Lumito AB and the Finnish company Uniogen Oy have signed a cooperation agreement for the production of Lumito’s immunohistochemical reagent kit, SCIZYS Erbium Kit. The reagent kit is part of Lumito’s product offering and is based on upconverted nanoparticles. Since June 2022, Lumito has had a Letter of Intent in place with Uniogen Oy (formerly […]
Lumito AB publishes Quarterly Report 2, 2023
First half of the year 1 January – 30 June 2023 Net sales amounted to KSEK 0 (0). Result after taxes amounted to KSEK -14,668 (-13,610). Basic and diluted earnings per share amounted to SEK -0.07 (-0.09). Cash flow from operating activities after change in working capital amounted to KSEK -13,734 (-14,636). Cash and cash […]
Lumito AB publishes Quarterly Report 3, 2022
Financial overview of the third quarter July 1 to September 30, 2022 Net sales amounted to TSEK 0 (0). Result after taxes amounted to TSEK -6 815 (-6 073). Earnings per share before and after dilution amounted to SEK -0.04 (-0.07). Cash flow from operating activities after changes in working capital amounted to TSEK -9 […]
The launch of SCIZYS by Lumito will be slightly delayed
As previously communicated, Lumito's ambition and plan has been to offer product for researchers use only by the end of 2022. Employees and production partners have together set the plan and worked hard and focused on fulfilling the ambition, which has been deemed fully realistic until now. Lumito therefore wishes to inform that the launch […]
Lumito publishes Quarterly Report 2, 2022
First half of the year 1 January–30 June 2022 Net sales amounted to KSEK 0 (0). Result after taxes amounted to KSEK -13,610 (-13,444). Basic and diluted earnings per share amounted to SEK -0.09 (-0.15) Cash flow from operating activities after change in working capital amounted to KSEK -14,636 (-12,883). Cash and cash equivalents amounted […]
Successful results from a pre-study completed in collaboration with Umeå University, Sweden, shows that Lumito’s technique offers better possibilities compared with other immunohistochemical methods
A now completed pre-study, initiated at the beginning of this year in collaboration with a research group at Umeå University in Sweden led by Assistant Professor Daniel Öhlund has yielded successful results. The research group intended to identify how Lumito's UCNP (Up-Converting Nano Particles) technology could be used to improve the ability to visualise protein […]
